(Q38066118)

28 August 2017

1 reference

title

Lipid effects of psychiatric medications (English)

1 reference

28 August 2017

Junzo Watanabe

1

1 reference

28 August 2017

Yutaro Suzuki

series ordinal

2

1 reference

28 August 2017

Toshiyuki Someya

series ordinal

3

1 reference

28 August 2017

publication date

1 January 2013

1 reference

Current Atherosclerosis Reports

28 August 2017

published in

1 reference

28 August 2017

volume

15

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

292

1 reference

Clustering of metabolic comorbidity in schizophrenia: a genetic contribution?

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

Schizophrenia: a concise overview of incidence, prevalence, and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

National patterns in antidepressant medication treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

The impact of serious mental illness on health and healthcare

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

Mortality in a cohort of patients with schizophrenia: a record linkage study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

Schizophrenia and increased risks of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

Mortality and causes of death in schizophrenia in Stockholm county, Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

Physical consequences of schizophrenia and its treatment: the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

Antipsychotic-induced weight gain and therapeutic response: a differential association.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

Diabetes mellitus in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

Insulin and leptin levels in patients with schizophrenia or related psychoses--a comparison between different antipsychotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

Bidirectional association between depression and type 2 diabetes mellitus in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

Major depression as a risk factor for high blood pressure: epidemiologic evidence from a national longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

Depressive Symptoms and Risk of Stroke: The Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

Role of depression and inflammation in incident coronary heart disease events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

The association of depression and anxiety with obesity and unhealthy behaviors among community-dwelling US adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

Consensus development conference on antipsychotic drugs and obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

A clinical study of the association of antipsychotics with hyperlipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

Use of Metabolic Markers To Identify Overweight Individuals Who Are Insulin Resistant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

HDL as a target in the treatment of atherosclerotic cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

Insulin resistance and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

Hyperglycemia and hypertriglyceridemia secondary to olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

Quetiapine-associated hyperglycemia and hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

Olanzapine and hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

Hyperlipidemia--side-effect of the treatment with an atypical antipsychotic (zotepine)?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

Association between depressive symptoms and metabolic syndrome is not explained by antidepressant medication: results from the PPP-Botnia Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0292-6

Diet, diabetes and schizophrenia: review and hypothesis.

21 January 2018

1 reference

12 December 2020

The distribution of body mass index among individuals with and without schizophrenia.

1 reference

12 December 2020

The risk of developing type 2 diabetes mellitus associated with psychotropic drug use in children and adolescents: a retrospective cohort analysis

1 reference

12 December 2020

The unhealthy lifestyle of people with schizophrenia

1 reference

12 December 2020

Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome

1 reference

12 December 2020

The lipid profiles in Japanese patients with schizophrenia treated with antipsychotic agents

1 reference

12 December 2020

Effects of atypical antipsychotics on weight and serum lipid levels

1 reference

12 December 2020

Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada.

1 reference

12 December 2020

Antipsychotic-induced weight gain: a comprehensive research synthesis

1 reference

12 December 2020

Serum triglyceride levels in patients treated with clozapine

1 reference

12 December 2020

A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year

1 reference

12 December 2020

Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia

1 reference

12 December 2020

10.1007/S11883-012-0292-6

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1028667105

0 references

1 reference